Rhythm Biosciences Past Earnings Performance
Past criteria checks 0/6
Rhythm Biosciences's earnings have been declining at an average annual rate of -19.8%, while the Healthcare industry saw earnings growing at 10.6% annually. Revenues have been growing at an average rate of 25.6% per year.
Key information
-19.8%
Earnings growth rate
-4.2%
EPS growth rate
| Healthcare Industry Growth | 15.7% |
| Revenue growth rate | 25.6% |
| Return on equity | -790.7% |
| Net Margin | -405.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Rhythm Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 2 | -7 | 3 | 2 |
| 31 Mar 24 | 2 | -8 | 4 | 3 |
| 31 Dec 23 | 2 | -9 | 5 | 4 |
| 30 Sep 23 | 3 | -8 | 6 | 4 |
| 30 Jun 23 | 3 | -8 | 8 | 4 |
| 31 Mar 23 | 3 | -8 | 7 | 4 |
| 31 Dec 22 | 3 | -8 | 6 | 5 |
| 30 Sep 22 | 3 | -9 | 6 | 5 |
| 30 Jun 22 | 2 | -9 | 6 | 5 |
| 31 Mar 22 | 2 | -9 | 6 | 5 |
| 31 Dec 21 | 2 | -9 | 5 | 5 |
| 30 Sep 21 | 2 | -8 | 4 | 5 |
| 30 Jun 21 | 1 | -7 | 3 | 5 |
| 31 Mar 21 | 1 | -5 | 3 | 3 |
| 31 Dec 20 | 1 | -4 | 3 | 2 |
| 30 Sep 20 | 1 | -4 | 2 | 2 |
| 30 Jun 20 | 0 | -4 | 2 | 2 |
| 31 Mar 20 | 0 | -4 | 2 | 1 |
| 31 Dec 19 | 1 | -3 | 2 | 1 |
| 30 Sep 19 | 1 | -3 | 2 | 1 |
| 30 Jun 19 | 1 | -3 | 3 | 1 |
| 31 Mar 19 | 1 | -3 | 2 | 1 |
| 31 Dec 18 | 0 | -3 | 2 | 1 |
| 30 Sep 18 | 0 | -2 | 2 | 1 |
| 30 Jun 18 | 0 | -2 | 1 | 0 |
Quality Earnings: 0RY is currently unprofitable.
Growing Profit Margin: 0RY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0RY is unprofitable, and losses have increased over the past 5 years at a rate of 19.8% per year.
Accelerating Growth: Unable to compare 0RY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0RY is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (40.5%).
Return on Equity
High ROE: 0RY has a negative Return on Equity (-790.71%), as it is currently unprofitable.